 |
|||
CBI's lead human pharmaceutical, HepArrest™ is a new heparin binding peptide compound used primarily during open-heart surgery. During cardiovascular procedures, the intense blood thinning effects of the anticoagulant heparin must e reversed to restore normal blood clotting at the end of the surgery. This reversal prevents unwanted bleeding and related post-operative complications. Protamine, the only available approved antidote, causes frequent toxic side effects. If approved by the FDA, HepArrest™ is intended for use as a safe, effective antidote for the anticoagulant effects of heparin. |
|||
|
|||
© Internet Creations |
|||
